Mumbai, January 19, 2018: Panacea Biotec has signed two long term agreements with Serum Institute of India (SII) and SII’s wholly owned subsidiary, Bilthovan Biologicals B.
Under the collaboration, SII is entitled to manufacture and sell fully liquid whole cell pertussis (wP) and salk based injectable polio vaccine (IPV) based hexavalent vaccine developed and commercialised by Panacea Biotec, a first of its king in this category.
Under the collaboration, Serum Institute of India will ensure supply of IPV bulk to Panacea Biotech, an important constituent of the Hexavalent vaccine, from its wholly owned subsidiary BBIO, a bioengineering and pharmaceutical company, registered in the Netherlands having technology and expertise for making the IPV, earlier possessed by only 3 other vaccine manufacturers in the world.
United News of India
By Dr. Priyanka Kuri, Consultant - Dermatology, Aster Whitefield Hospital, Bengaluru Insomnia, the persistent inability…
Illuminating Latest Advances in Migraine Diagnosis and Treatment New Delhi, December 21, 2024: In a…
New Delhi, December 20, 2024: The healthcare sector is undergoing a transformation fueled by technological…
National, December 20, 2024: DKMS just published its first Global Impact Report that outlines the organization's…
Ahmedabad, December 19, 2024: Sterling Biotech Limited, a joint venture between Perfect Day and Zydus, has…
New Delhi, December 19, 2024: Antara Senior Care, an integrated eco-system provider for lifestyle and…